JP7691823B2 - 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物 - Google Patents

可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物 Download PDF

Info

Publication number
JP7691823B2
JP7691823B2 JP2020549021A JP2020549021A JP7691823B2 JP 7691823 B2 JP7691823 B2 JP 7691823B2 JP 2020549021 A JP2020549021 A JP 2020549021A JP 2020549021 A JP2020549021 A JP 2020549021A JP 7691823 B2 JP7691823 B2 JP 7691823B2
Authority
JP
Japan
Prior art keywords
antibody
seq
agent
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020549021A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019175885A5 (https=
JP2021517152A (ja
JP2021517152A5 (https=
Inventor
ハキーム，モッティ
アリシェケヴィッツ，ドロール
ジヴ，デーナ ハヴェス
メイリン，エドナ
サピール，ヤイール
シュルマン，アヴィドール
ベン－モーシェ，テヒラ
マンデル，ヤーナ
Original Assignee
ビオンド バイオロジクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオンド バイオロジクス リミテッド filed Critical ビオンド バイオロジクス リミテッド
Publication of JP2021517152A publication Critical patent/JP2021517152A/ja
Publication of JPWO2019175885A5 publication Critical patent/JPWO2019175885A5/ja
Publication of JP2021517152A5 publication Critical patent/JP2021517152A5/ja
Application granted granted Critical
Publication of JP7691823B2 publication Critical patent/JP7691823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020549021A 2018-03-15 2019-03-14 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物 Active JP7691823B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862643355P 2018-03-15 2018-03-15
US201862643334P 2018-03-15 2018-03-15
US62/643,355 2018-03-15
US62/643,334 2018-03-15
US201862774254P 2018-12-02 2018-12-02
US62/774,254 2018-12-02
PCT/IL2019/050292 WO2019175885A1 (en) 2018-03-15 2019-03-14 Methods and compositions for decreasing soluble immune receptor cd28

Publications (4)

Publication Number Publication Date
JP2021517152A JP2021517152A (ja) 2021-07-15
JPWO2019175885A5 JPWO2019175885A5 (https=) 2022-03-23
JP2021517152A5 JP2021517152A5 (https=) 2022-03-23
JP7691823B2 true JP7691823B2 (ja) 2025-06-12

Family

ID=66182618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020549021A Active JP7691823B2 (ja) 2018-03-15 2019-03-14 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物

Country Status (10)

Country Link
US (2) US12139534B2 (https=)
EP (1) EP3765518A1 (https=)
JP (1) JP7691823B2 (https=)
KR (1) KR20200131260A (https=)
CN (2) CN112074539B (https=)
AU (1) AU2019234183B2 (https=)
BR (1) BR112020018279A2 (https=)
CA (1) CA3093647A1 (https=)
IL (1) IL277354B2 (https=)
WO (1) WO2019175885A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12139534B2 (en) 2018-03-15 2024-11-12 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28
US20220153845A1 (en) * 2019-03-14 2022-05-19 Biond Biologics Ltd. A method for immunosuppression
WO2020183473A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. Small shedding blocking agents
EP4070099A4 (en) * 2019-12-02 2024-03-20 Biond Biologics Ltd. SOLUBLE CD28 LEVELS DURING IMMUNOTHERAPY
US20230221325A1 (en) * 2019-12-02 2023-07-13 Biond Biologics Ltd. Soluble cd28 levels after immunotherapy
EP4069299A4 (en) * 2019-12-02 2024-06-12 Biond Biologics Ltd. Use of mmp inhibition
US12589163B2 (en) 2020-03-12 2026-03-31 Biond Biologics Ltd. Shedding blocking agents with increased stability
JP2024532970A (ja) 2021-09-06 2024-09-11 ビオンド バイオロジックス リミテッド Ｃｄ２８シェディング遮断剤
US20250281536A1 (en) * 2022-03-31 2025-09-11 Sana Biotechnology, Inc. Cd4-specific antibody constructs and compositions and uses thereof
WO2025149029A1 (zh) * 2024-01-12 2025-07-17 信达生物制药(苏州)有限公司 抗cd28抗体及其用途
WO2025215647A1 (en) 2024-04-11 2025-10-16 Biond Biologics Ltd. Combination cancer treatment with staggered dosing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2353273T3 (es) * 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL148993A0 (en) 2002-04-04 2002-11-10 Yissum Res Dev Co Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
NZ543102A (en) 2003-04-24 2008-12-24 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
GB0400440D0 (en) * 2004-01-09 2004-02-11 Isis Innovation Receptor modulators
CN100509849C (zh) 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
AR072571A1 (es) 2008-07-18 2010-09-08 Bristol Myers Squibb Co Composiciones monovalentes para union a cd28 y procedimientos de uso
US12139534B2 (en) 2018-03-15 2024-11-12 Biond Biologics Ltd. Methods and compositions for decreasing soluble immune receptor CD28

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Centr. Eur. J. Immunol. ，2014年，39 (2)，pp.216-222，DOI: 10.5114/ceji.2014.43726
現代免疫学，2007年，27(1)，pp.38-40

Also Published As

Publication number Publication date
US20240309094A1 (en) 2024-09-19
CN119775419A (zh) 2025-04-08
US20210047411A1 (en) 2021-02-18
JP2021517152A (ja) 2021-07-15
BR112020018279A2 (pt) 2020-12-29
IL277354B2 (en) 2025-07-01
CN112074539A (zh) 2020-12-11
KR20200131260A (ko) 2020-11-23
AU2019234183B2 (en) 2025-12-18
CA3093647A1 (en) 2019-09-19
IL277354B1 (en) 2025-03-01
WO2019175885A1 (en) 2019-09-19
CN112074539B (zh) 2025-01-24
EP3765518A1 (en) 2021-01-20
IL277354A (en) 2020-11-30
US12139534B2 (en) 2024-11-12
AU2019234183A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7691823B2 (ja) 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物
CA3110750A1 (en) Single-domain antibodies against cd33 and constructs thereof
JP7685954B2 (ja) 低分子脱落遮断剤
JP2023509803A (ja) Ｍｍｐ抑制の使用
CN115515982A (zh) 具有增加的稳定性的脱落阻断剂
EP4688842A1 (en) Il-10 receptor antibodies and methods of use thereof
HK40064257A (en) Small shedding blocking agents
US12612459B2 (en) Methods of identifying agents that block MCD28 cleavage by MMPS
WO2024176224A1 (en) Antibodies against hla-e and use thereof
HK40068325A (en) Anti-hvem antibodies and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250602

R150 Certificate of patent or registration of utility model

Ref document number: 7691823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150